$LFST

Bessler Robert sold $9.1M of LFST (indirect holdings)

Bessler Robert sold 894,337 indirectly-held shares of LifeStance Health Group, Inc. (LFST) at $10.13 ($9.06M total) across 2 trades on 2026-06-26 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Bessler Robert
Published Jun 30, 2026, 8:52 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 30, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LFST
Neutral
medium confidence
Mentioned
$LFST
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LFSTNeutralLow
01

Why it matters

Provides a concrete, newly filed datapoint on insider selling size, price, and post-transaction holdings, which can affect short-term sentiment but not fundamentals by itself.

02

Market read

Traders may monitor for follow-on insider activity, but the 10b5-1 framing generally limits the signal strength.

03

What to watch

The disclosure is indirect holdings and pre-arranged; without additional context (e.g., total insider activity, other filings), directional inference is weak.

Relevance 5/10Novelty 5/10Timing: Filed 2026-06-30; transaction dated 2026-06-26 (after-hours/next-session read-through).

Background

The article is an SEC Form 4 insider transaction: director Robert Bessler sold LifeStance Health Group shares via an open-market sale under a Rule 10b5-1 plan.

Company-level read

Ticker impact

$LFSTNeutralMedium confidence
Context

LifeStance Health Group director Robert Bessler sold 894,337 shares in an open-market transaction under a 10b5-1 plan at $10.13.

Expected impact

Likely limited immediate impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction size and price, but it explicitly states a pre-arranged 10b5-1 plan, reducing interpretive weight.

Market effects

No sector-level read-across; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, large sales can coincide with personal liquidity needs or risk management, which some traders may still interpret as caution.

Key entities

  • LifeStance Health Group, Inc.

    Subject of the Form 4 insider transaction; director Robert Bessler sold shares under a 10b5-1 plan.

  • Robert Bessler

    Director who executed the open-market sale; transaction disclosed on SEC EDGAR.

Related articles

$LFSTMedAI 8/10

LifeStance Health Group, Inc. Q2 2026 Earnings Call Summary

LifeStance Health Group reported Q2 2026 revenue growth of 26%, driven by higher visit volumes and a 6% rise in revenue per visit, and said visits per clinician rose 7% YoY. The company raised full-year 2026 guidance to $1.685B-$1.725B revenue and 13.2% adjusted EBITDA margins, approved a new $100M buyback, and reported Q2 free cash flow of $88M.

$LFSTHighAI 9/10

LifeStance (LFST) Q2 2026 Earnings Call Transcript

LifeStance (LFST) reported Q2 2026 results on an earnings call. Revenue rose to $435 million (+26%) on 2.6 million visits (+19%) and total revenue per visit of $167 (+6%). Adjusted EBITDA was $66 million (+94%) with a 15.2% margin. Full-year 2026 revenue guidance was raised to $1.685-$1.725 billion and adjusted EBITDA to $215-$235 million.

$LFSTMedAI 8/10

LifeStance Health: Q2 Earnings Snapshot

LifeStance Health Group Inc. (LFST) reported Q2 net income of $23.6 million, or 6 cents per share, topping Wall Street expectations. Revenue was $435.4 million versus an expected $414.3 million, according to Zacks Investment Research. For the quarter ending September, the company forecast revenue of $420 million to $440 million, and full-year revenue of $1.69 billion to $1.73 billion.

$LFSTHigh

LifeStance Health Group, Inc. (LFST): Results of Operations and Financial Condition

LifeStance Health Group, Inc. (LFST) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lfst-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Investor Relations Contact Monica Prokocki VP of Finance & Investor Relations 602-767-2100 investor.relations@lifestance.com LifeStance Reports Strong Second Quarter 2026 Financial Results and Raises Full Year Outlook Announc